Neurogenesis NEUN Stock
Neurogenesis Price Chart
Neurogenesis NEUN Financial and Trading Overview
Neurogenesis stock price | 0.0001 USD |
Previous Close | 0.0001 USD |
Open | 0.0001 USD |
Bid | 0 USD x 0 |
Ask | 0 USD x 0 |
Day's Range | 0.0001 - 0.0001 USD |
52 Week Range | 0.0001 - 0.0075 USD |
Volume | 5K USD |
Avg. Volume | 163 USD |
Market Cap | 8.23K USD |
Beta (5Y Monthly) | -18.130985 |
PE Ratio (TTM) | Infinity |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
NEUN Valuation Measures
Enterprise Value | 2.03K USD |
Trailing P/E | Infinity |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.007691725 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 0.002 |
Enterprise Value/EBITDA | N/A |
Trading Information
Neurogenesis Stock Price History
Beta (5Y Monthly) | -18.130985 |
52-Week Change | -98.66% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.0075 USD |
52 Week Low | 0.0001 USD |
50-Day Moving Average | 0.0001 USD |
200-Day Moving Average | 0.004392 USD |
NEUN Share Statistics
Avg. Volume (3 month) | 163 USD |
Avg. Daily Volume (10-Days) | 0 USD |
Shares Outstanding | 82.26M |
Float | N/A |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 0% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2006 |
Most Recent Quarter (mrq) | June 30, 2012 |
Next Fiscal Year End | December 31, 2007 |
Profitability
Profit Margin | -0.89% |
Operating Margin (ttm) | -0.088% |
Gross Margin | 79.62% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | N/A |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 1.07M USD |
Revenue Per Share (ttm) | 0.02 USD |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 1.06M USD |
EBITDA | N/A |
Net Income Avi to Common (ttm) | -9602 USD |
Diluted EPS (ttm) | 0 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | N/A |
Total Cash Per Share (mrq) | N/A |
Total Debt (mrq) | N/A |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 4.449 |
Book Value Per Share (mrq) | -0.004 |
Cash Flow Statement
Operating Cash Flow (ttm) | N/A |
Levered Free Cash Flow (ttm) | N/A |
Profile of Neurogenesis
Country | United States |
State | TX |
City | League City |
Address | 1241 Butler Road |
ZIP | 77573 |
Phone | 281 557 7877 |
Website | https://www.neurogenesis.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm'd, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long-term use of alcohol. It also provides NeuReplenish, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of chemical stimulants; NeuRelieve, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of antianxiety drugs, and to be used in conjunction with professional support during the tapering process; and NeuSlim, which aids in the reduction of cravings (or urges) for simple carbohydrates, to reduce excessive appetite in general, and to assist in healthy moderation of nutritional needs. In addition, the company offers NeuBecalm'd/NeuRelieve Combo, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the prolonged use of prescription pain pills or from the use of opiate drugs, such as heroin or methadone, as well as used in conjunction with professional support during the tapering process. Neurogenesis, Inc. has a research collaboration with the University of Edinburgh for the development of various platform approaches to enable gene therapies. The company was founded in 1984 and is headquartered in League City, Texas.
Q&A For Neurogenesis Stock
What is a current NEUN stock price?
Neurogenesis NEUN stock price today per share is 0.0001 USD.
How to purchase Neurogenesis stock?
You can buy NEUN shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Neurogenesis?
The stock symbol or ticker of Neurogenesis is NEUN.
Which industry does the Neurogenesis company belong to?
The Neurogenesis industry is Drug Manufacturers-Specialty & Generic.
How many shares does Neurogenesis have in circulation?
The max supply of Neurogenesis shares is 82.26M.
What is Neurogenesis Price to Earnings Ratio (PE Ratio)?
Neurogenesis PE Ratio is now.
What was Neurogenesis earnings per share over the trailing 12 months (TTM)?
Neurogenesis EPS is 0 USD over the trailing 12 months.
Which sector does the Neurogenesis company belong to?
The Neurogenesis sector is Healthcare.